# Progress Note 02 — Focused Visit (Intermediate follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frances Burney (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN013-SYN
- Date: 2026-08-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harriet Pell, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Intermediate follow-up)

## Chief complaint

Review of breast imaging and biopsy results. **S**

## History of present illness

Mrs. Burney returns two weeks after presenting with a right breast lump and a year of heavy, dull breast ache. The diagnostic mammogram and ultrasound twelve days ago showed a 2.4 cm spiculated mass at 10 o'clock in the right breast, BI-RADS 5, with normal axillary nodes and dense breast tissue. The ultrasound-guided core biopsy ten days ago shows invasive ductal carcinoma, grade 2, strongly estrogen and progesterone receptor positive and HER2 negative. The ache is unchanged and does not wake her. She has no bone pain, cough, headaches, abdominal pain, or weight loss. She saw Dr. Marsh of breast surgery this morning. She is frightened of an operation and has asked that every step be explained beforehand and that she be warned before anything is done; with that, she feels able to go ahead. She has no family history of breast or ovarian cancer that she knows of, but her mother died when she was ten and little is known of her mother's family. **S**

| Element | Detail |
|---|---|
| Interval change | Imaging BI-RADS 5; core biopsy invasive ductal carcinoma, ER and PR positive, HER2 negative |
| Symptoms | Unchanged dull ache; no symptoms of spread |
| Coordination | Breast surgery seen this morning |
| Family history | Limited: mother died when she was ten |
| Concerns | Fear of surgery; wants each step explained and to be warned in advance |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No weight loss, fever, or night sweats |
| Breast | Positive | Right breast lump with a dull ache; no nipple discharge or skin change |
| Musculoskeletal | Negative | No bone pain |
| Respiratory | Negative | No cough or breathlessness |
| Neurological | Negative | No headaches |
| Psychiatric | Positive | Worried and sleeping less since the diagnosis; PHQ-9 5, GAD-7 7 |

6 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 132/82 mmHg; pulse 86 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 61.6 kg; BMI 24.1 kg/m². All vital signs are synthetic.

PHQ-9: 5; GAD-7: 7. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Anxious but composed |
| Breasts | Right breast: 2.5 cm hard, irregular mass at 10 o'clock, mobile on the chest wall, with a small bruise from the biopsy; no skin dimpling or nipple change. Left breast normal |
| Lymph nodes | No axillary, supraclavicular, or infraclavicular nodes |
| Abdomen | Soft; liver not enlarged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Invasive ductal carcinoma of the right breast, clinical stage T2 N0 (cT2 cN0 M0), hormone receptor positive, HER2 negative** (C50.411). Early breast cancer. With no symptoms of spread and a clinical stage of T2 N0, staging scans and tumor markers are not indicated. Because the breasts are dense, Dr. Marsh advises MRI before choosing between breast-conserving surgery and mastectomy. **S**
   - Bilateral breast MRI in four days, as Dr. Marsh advised.
   - Germline multigene panel test sent today, before surgery, as recommended for breast cancer at 65 or younger.
   - Surgery date to be set after the MRI and the genetic result; pre-anesthesia clinic visit to be booked.
   - She will be told in advance of every procedure, as she asked.
2. **Estrogen receptor positive status** (Z17.0). ER 95 percent and PR 70 percent: she will benefit from endocrine therapy after surgery. **S**
   - Recurrence score on the surgical specimen to decide whether chemotherapy would add benefit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Diagnostic mammography and ultrasound of the breast and axilla | At presentation with a palpable mass | Up to date | Done twelve days ago: 2.4 cm spiculated mass, BI-RADS 5; normal axillary nodes; dense breasts |
| Laboratory | Core biopsy with ER, PR, and HER2 testing | At diagnosis | Up to date | Invasive ductal carcinoma, grade 2; ER 95 percent, PR 70 percent, HER2 1+ (negative), Ki-67 15 percent |
| Imaging | Breast MRI for extent of disease | Optional at diagnosis; considered for dense breasts or when surgical planning is uncertain | Ordered | Booked in four days |
| Imaging | CT, bone scan, or PET for distant spread | Only with symptoms or clinical stage III | Not indicated | Clinical stage T2 N0 with no symptoms of spread |
| Laboratory | Tumor markers (CEA, CA 15-3, CA 27.29) | Not recommended for early breast cancer | Not indicated | Not ordered |
| Laboratory | Germline genetic testing | At diagnosis, for breast cancer at 65 or younger | Completed today | Multigene panel sample sent today; result expected in about three weeks, before surgery |
| Survey | Distress, depression, and anxiety screen (PHQ-9 and GAD-7) | At diagnosis and at periodic intervals | Completed today | PHQ-9 5 and GAD-7 7, mild; supported today and offered the cancer center's counseling service |
| Examination | Lymphedema baseline arm measurements | Before axillary surgery | Due | To be measured at the pre-anesthesia visit before surgery |
| Referral | Breast surgery | At diagnosis | Completed today | Seen this morning; recommendations in the consultation note |
| Referral | Medical oncology | After surgery, with the surgical pathology | Due | To review the pathology and recurrence score after surgery |
| Medication safety | Pre-anesthesia evaluation | Before surgery | Ordered | Pre-anesthesia clinic visit to be booked once the date is set |
| Self-management | Activity and preparation for surgery | Every visit | Completed today | Walking 30 minutes a day; never smoker; shoulder exercise leaflet given |

## Goal progress

- Complete diagnosis, staging, and surgery within eight weeks of presentation. In progress; target 2026-10-19. **S**
- Surgery under anesthesia with pain controlled without opioids after discharge. In progress; target 2026-10-19. **S**
- Start adjuvant endocrine therapy with a bone-health plan. In progress; target 2026-10-19. **S**
- Regain full right shoulder movement and keep lymphedema risk low. In progress; target 2026-10-29. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025), National Comprehensive Cancer Network
- Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024 (2024), American Society of Clinical Oncology and Society of Surgical Oncology
- CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026), Aether Forge

## Follow-up

- Breast MRI in four days. Genetic result in about three weeks. Surgery date from the breast surgery team. Primary care review about three weeks after surgery. **S**
- Next scheduled visit 2026-10-19: review three weeks after right mastectomy; start of endocrine therapy and survivorship care. **S**
